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The past decades have seen a tremendous rise in the use of
methylphenidate in children and adolescents. While the
overall prevalence of psychotropic drug use in children and
adolescents in the Netherlands doubled between 1995 and
2001, that of methylphenidate alone almost rose sixfold in
those years [1]. Between 2001 and 2006, a further large
increase was observed in the prescription rates of methyl-
phenidate, not only in children and adolescents but also in
adults [2]. While rates of methylphenidate use are still
clearly highest amongst boys aged 6–11 years, the most
rapid increase in prevalence rate of methylphenidate use
has actually been seen in girls. Between 1996 and 2006 this
has risen more than 11.5-fold in girls, according to a
pharmacoepidemiological study conducted in the North of
the Netherlands [3]. To put this into perspective: the latter
study pointed out that the use of methylphenidate in girls in
2006 was almost double that of boys back in 1996.
The increased use of methylphenidate contrasts with the
lack of long term data on safety and effectiveness. Much of
our knowledge about treatment periods of longer than a
year comes from following up one study, the Multimodal
Treatment of attention deﬁcit/hyperactivity (ADHD) study
(MTA) study. Although it should not be forgotten that all
MTA data beyond the initial controlled period of
14 months has been strictly observational, so far long term
beneﬁts of optimized and well controlled methylphenidate
treatment during a limited period of time of 14 months
have been hard to demonstrate [4]. Thus, while on one
hand, there are clear short-term beneﬁts of methylphenidate
for the treatment of ADHD, the uncertainty of long term
beneﬁts and risks remains an urgent challenge for the sci-
entiﬁc and clinical community.
What promise may alternative treatments offer for
children with ADHD? Food-based interventions may be
one option. In 2009, this Journal had published promising
effects of a restricted elimination diet in reducing symp-
toms of ADHD versus a waiting list control group [5].
Results were recently conﬁrmed in a larger scale Lancet
study by the same group of investigators, in which there
was a control group that received instructions for a healthy
diet [6]. However, the difﬁculty of establishing a truly
blinded control intervention constitutes perhaps the biggest
design challenge in trying to more ﬁrmly demonstrate the
efﬁcacy of food-based treatments for ADHD. Ideally, well-
designed and controlled replication studies should be
conducted by independent groups who did not develop the
intervention themselves.
Another alternative treatment option that has now seen a
number of randomized controlled trials is electroencepha-
logram (EEG)-based neurofeedback. This issue (Bakhsha-
yesh et al.) contains a small-scale, but elegantly designed
randomized controlled trial of EEG neurofeedback versus a
sham condition (biofeedback aimed at forehead muscle
relaxation). Importantly, children and parents were not
explicitly informed about the two treatment conditions.
Results indicated both speciﬁc effects of EEG neurofeed-
back (reduction of inattention symptoms on parent rating
scales and reaction time in neuropsychological tests), as
well as non-speciﬁc factors (regarding hyperactivity and
impulsivity), which were similarly improved in the chil-
dren receiving the sham treatment.
Another study in this issue (Benjet et al.), using an
epidemiological approach (based on interview data of more
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Mental Health Survey) once more reminded us that it is not
all genetics and neurobiology that determines mental dis-
orders. Rather, it pointed to the important role of family
dysfunctioning for the development of psychopathology.
As the authors conclude, their study ﬁndings at least indi-
rectly provide further evidence for the importance of
family focused intervention and prevention efforts.
With the ever rising prescription rates of methylpheni-
date, all too easily impressions of overtreatment rather than
undertreatment of ADHD in children may arise. However,
many children with impairing ADHD still receive no
proper treatment [7]. Thus, effective and easy-to-imple-
ment screening questionnaires that can identify those
children who are at risk of having ADHD or other
behavioral disorders are crucial. The Strengths and Difﬁ-
culties Questionnaire (SDQ) is one well-known example of
a brief screening instrument. Ullebø and colleagues [8]i n
this issue describe that already the use of the 5-item-only
SDQ hyperactivity- inattention subscale has adequate
sensitivity for detecting ADHD combined subtype.
Are we overtreating children with methylphenidate?
There may be both over- and undertreatment. It remains an
enormous challenge for the scientiﬁc community to more
precisely establish the long-term risks and beneﬁts of
methylphenidate treatment and also to determine in which
cases treatment with psychostimulants or alternative
treatments are warranted. Well-designed studies involving
alternative treatments remain urgently needed.
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